best emerging cryptocurrency 2021, searches

Centaline Property: The price of second-hand houses in Hong Kong dropped by 0.6% on a weekly basis. Centaline Property said on its website that in the week from December 2 to 8, the leading index of Central Plains cities, which measures the price of second-hand houses in Hong Kong, fell by 0.6% to 137.59.Citigroup: The target price of Illumina is lowered from $190 to $165, and the rating is lowered from "buy" to "neutral".Wen Ning Ke, former CEO of ASML, will be the chairman of the supervisory board of Heineken in April next year. Heineken Holdings announced on December 13th that Peter Wen Ning Ke, vice chairman of the supervisory board and former CEO of ASML, will be the chairman of the supervisory board in April next year, replacing Jean-Marc Huët. Wen Ning Ke joined the Board of Supervisors of Heineken at this year's annual general meeting of shareholders, and is an important member of the Audit Committee, Remuneration Committee and Selection and Appointment Committee.

On the 13th, coking coal fell by 2.15%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract coking coal closed at 2501, up or down by -2.15%, with a turnover of 104,800 lots. The position data showed that the top 20 seats were clear, and the difference position was 15,553 lots. The total contract turnover of coking coal futures was 180,200 lots, an increase of 8,845 lots over the previous day. The first 20 seats in the contract held 163,200 lots, an increase of 4,563 lots over the previous day. The short positions in the top 20 seats of the contract were 194,300 lots, an increase of 5,926 lots over the previous day. (Sina Futures)CITIC Jiantou: It maintains the "Buy" rating of Orrit, and its product line continues to expand and enrich. According to the research report of CITIC Jiantou Securities, Orrit (605116.SH) is one of the leading companies in the field of characteristic APIs in China. In recent years, the company's product line has been continuously expanded and enriched, which has promoted the continuous growth of revenue. At the same time, the company actively laid out potential areas, and at the current point of time, we think that we can see the company's follow-up multiple catalysis: 1) The preparation business continues to be heavy: the market development of diqu progesterone tablets continues to advance, and the estradiol/estradiol-diqu progesterone composite packaging tablets have been declared for listing. It is expected that the continuous enrichment of new pipelines for the follow-up preparation business will promote the company's performance growth. 2) Smegrutide API: The construction of fermentation workshop and synthesis workshop has been completed, and the expansion and release of new capacity will promote the good growth of API business. 3) Small nucleic acid business: The 100 kg commercial production line landed in September, 2004, opening up the space for subsequent growth. Maintain the "buy" rating.Hunan procuratorate prosecuted Wang Yonghong for alleged bribery and abuse of power according to law. Recently, the case of Wang Yonghong (deputy department level), former member of the Standing Committee of Shaoyang Municipal Committee of Hunan Province and former executive deputy mayor of the Municipal People's Government, was assigned jurisdiction by Hunan Provincial People's Procuratorate, and Loudi Municipal People's Procuratorate prosecuted Loudi Intermediate People's Court according to law. The case is being further processed. At the stage of examination and prosecution, the procuratorial organ informed the defendant Wang Yonghong of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of defenders. Loudi City People's Procuratorate sued the accusation that the defendant Wang Yonghong, as a national staff member, used his position to seek benefits for others and illegally accepted other people's property, with a huge amount; As a staff member of a state organ, he abuses his power, causing great losses to the interests of the state and the people. According to law, he should be investigated for criminal responsibility for accepting bribes and abusing his power.

The Zhuhai earthquake did not meet the emergency response standard, so citizens need not worry too much. On December 13th, some Zhuhai citizens felt obvious vibration, and many people suspected that an earthquake had occurred. Some citizens felt the vibration during lunch break, and some people felt the building shaking in the office. On the afternoon of the 13th, the reporter called the Seismological Bureau of Guangdong Province, and the relevant staff responded that at about 1: 25 noon on December 13th, a magnitude 2.1 earthquake occurred in the urban area of Zhuhai, so citizens need not worry too much. Because the magnitude of the earthquake did not reach the preset emergency response standard, the relevant departments did not start the emergency response mechanism, so the earthquake quick report information was not released. The staff member said that the bureau is also concerned about the public's concern about the earthquake, and is currently conducting corresponding research and judgment, and will issue corresponding research and judgment opinions later. (Nanfang Daily)On the 13th, coking coal fell by 2.15%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract coking coal closed at 2501, up or down by -2.15%, with a turnover of 104,800 lots. The position data showed that the top 20 seats were clear, and the difference position was 15,553 lots. The total contract turnover of coking coal futures was 180,200 lots, an increase of 8,845 lots over the previous day. The first 20 seats in the contract held 163,200 lots, an increase of 4,563 lots over the previous day. The short positions in the top 20 seats of the contract were 194,300 lots, an increase of 5,926 lots over the previous day. (Sina Futures)Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.